Explore

Rapid Read Rapid Read
MIT-Led Study Develops Adjuvant to Enhance Mucosal Immunity in Polio Vaccines

MIT-Led Study Develops Adjuvant to Enhance Mucosal Immunity in Polio Vaccines

Researchers at the Massachusetts Institute of Technology have developed an experimental adjuvant that could enhance mucosal immunity when used with injectable polio vaccines. The adjuvant, Am80, is delivered using lipid nanoparticles, allowing for a slow release that stimulates immune cells to target the mucosal lining of the intestine. This approach aims to provide the benefits of the oral polio vaccine, which induces mucosal immunity, without its associated risks. Initial tests in rats have shown promising results, with increased production of antibodies necessary for mucosal immunity.
Rapid Read Rapid Read
POP Biotechnologies Receives $9.7 Million CEPI Funding for Vaccine Development

POP Biotechnologies Receives $9.7 Million CEPI Funding for Vaccine Development

POP Biotechnologies, a Buffalo-based biotech company, has secured up to $9.7 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its SNAP nanoparticle vaccine platform into Phase 1 clinical trials. The funding will support the development of a vaccine candidate targeting H5N1 avian influenza, leveraging the SNAP platform's ability to enhance immune responses through protein-tagging technology. This investment builds on a previous $1.5 million award from CEPI, aimed at accelerating the development of vaccines against epidemic and pandemic threats.
Rapid Read Rapid Read
MIT Study Explores Enhanced Mucosal Immunity for Injectable Polio Vaccines

MIT Study Explores Enhanced Mucosal Immunity for Injectable Polio Vaccines

Researchers at the Massachusetts Institute of Technology (MIT) have developed an experimental adjuvant that could enhance mucosal immunity when used with injectable polio vaccines. The study, published in Science Advances, suggests that the adjuvant, known as Am80, can be delivered using lipid nanoparticles to stimulate immune cells to target the mucosal lining of the intestine. This approach aims to combine the safety of the injectable polio vaccine with the mucosal immunity typically provided by the oral polio vaccine, which some countries have stopped using due to a small risk of infection.
Rapid Read Rapid Read
MIT Researchers Develop Adjuvant to Enhance Injectable Polio Vaccine's Mucosal Immunity

MIT Researchers Develop Adjuvant to Enhance Injectable Polio Vaccine's Mucosal Immunity

Researchers at the Massachusetts Institute of Technology have developed a new adjuvant that could enhance the mucosal immunity of the injectable polio vaccine. The injectable form of the polio vaccine is effective at preventing illness but does not block virus transmission as effectively as the oral version. The oral vaccine induces a mucosal immune response in the gastrointestinal tract, which is the primary site of virus exposure. However, due to a small risk of infection, several countries have stopped using the oral vaccine. The new adjuvant, known as Am80, is delivered with a lipid nanoparticle that releases it slowly, allowing for a sustained immune response. This approach aims to combine the safety of the injectable vaccine with the mucosal immunity benefits of the oral vaccine, potentially aiding in polio eradication efforts.
Rapid Read Rapid Read
MIT Study Suggests Injectable Polio Vaccine Could Gain Mucosal Immunity with New Adjuvant

MIT Study Suggests Injectable Polio Vaccine Could Gain Mucosal Immunity with New Adjuvant

Researchers at the Massachusetts Institute of Technology (MIT) have developed a new approach to enhance the injectable polio vaccine by incorporating a nanoparticle-based adjuvant. This innovation aims to induce mucosal immunity, which is typically achieved through the oral polio vaccine. The oral vaccine, while effective in preventing virus transmission, carries a small risk of infection, leading some countries to discontinue its use. The MIT team, led by Ana Jaklenec, PhD, has created an injectable vaccine that includes an adjuvant derived from vitamin A, encapsulated in lipid nanoparticles. This formulation is designed to direct immune cells to the mucosal lining of the intestine, potentially reducing virus shedding and transmission. Initial tests in rats have shown promising results, with a significant increase in mucosal antibodies compared to the standard injectable vaccine.
Trendline Trendline
AstraZeneca CEO Highlights AI's Role in Enhancing Drug Development Success

AstraZeneca CEO Highlights AI's Role in Enhancing Drug Development Success

AstraZeneca CEO Highlights AI's Role in Enhancing Drug Development Success
Rapid Read Rapid Read
Rockefeller University Study Reveals New Insights into Antibody Generation in Germinal Centers

Rockefeller University Study Reveals New Insights into Antibody Generation in Germinal Centers

A recent study conducted by researchers at The Rockefeller University has provided new insights into how germinal centers (GCs) in mice produce highly effective antibodies. The research, led by Gabriel D. Victora, PhD, challenges the traditional view that GCs function as selection machines sorting out the best antibodies. Instead, the study suggests that the process is more akin to random evolution, with B cells undergoing rapid mutation and competition to improve antibody affinity. The findings, published in the journal Cell, could have significant implications for vaccine development against rapidly mutating pathogens like influenza and HIV.
Rapid Read Rapid Read
Study Reveals Germinal Centers' Role in Antibody Evolution Through Random Mutation

Study Reveals Germinal Centers' Role in Antibody Evolution Through Random Mutation

A recent study conducted by Gabriel D. Victora, PhD, and his team at The Rockefeller University has unveiled new insights into how germinal centers (GCs) function in the immune system. The research, published in the journal Cell, challenges the traditional view of GCs as mere selection machines for antibodies. Instead, the study reveals that the process of antibody evolution within GCs is more akin to a random, evolutionary process rather than a deterministic one. By tracking thousands of B cells across more than 100 GCs in mice, the researchers found that antibody improvement is not solely driven by rare growth bursts among successful B cells. Instead, the process involves a series of random mutations and selections that eventually lead to the production of highly effective antibodies. This discovery could have significant implications for understanding immune cell evolution and designing vaccines against rapidly mutating pathogens like influenza.
Rapid Read Rapid Read
Chitosan Nanoparticles Offer New Hope for Stable, Needle-Free Vaccines

Chitosan Nanoparticles Offer New Hope for Stable, Needle-Free Vaccines

A recent review in npj Vaccines highlights the potential of chitosan-based nanovaccines to enhance vaccine stability and delivery. Chitosan, a natural polymer, is used to create nanostructures that protect antigens and boost immune responses. These nanovaccines could reduce reliance on cold-chain storage and enable needle-free administration. Initial studies show promising safety profiles and immune responses, but human trials have been inconsistent. The review emphasizes the need for standardized chitosan materials to ensure reproducible production and clinical efficacy.
Rapid Read Rapid Read
Immune Cell Phenotyping Advances Understanding of Disease Biology

Immune Cell Phenotyping Advances Understanding of Disease Biology

Recent advancements in immune cell phenotyping have provided new insights into disease biology, particularly in chronic conditions. Researchers have developed methods to profile plasma membrane order across various immune cell types, revealing distinct cell states that are not detectable through traditional markers. This approach has been applied to study patients with long COVID and chronic lymphocytic leukemia, uncovering unique subsets of natural killer (NK) cells with varying cytotoxic potential and migratory capacity. These findings could lead to new therapeutic strategies and improve our understanding of immune system dysfunction.
Trendline Trendline
HotSpot Therapeutics Unveils Preclinical Data on IRF5 Inhibitors at EULAR 2026

HotSpot Therapeutics Unveils Preclinical Data on IRF5 Inhibitors at EULAR 2026

HotSpot Therapeutics Unveils Preclinical Data on IRF5 Inhibitors at EULAR 2026
Trendline Trendline
Fujifilm Expands Leadership Roles to Boost Life Sciences Capabilities

Fujifilm Expands Leadership Roles to Boost Life Sciences Capabilities

Fujifilm Expands Leadership Roles to Boost Life Sciences Capabilities